Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Trial Details
- NCT ID
- NCT06450106
- Phase
- PHASE1
- Sponsor
- SURGE Therapeutics
- Status
- RECRUITING
- Cancer Type
- Prostate Cancer
- Interventions
- Locations (sample)
- Tucson, Arizona, United States|32.22174,-110.92648
- Gainesville, Florida, United States|29.65163,-82.32483
- Melbourne N., Victoria, Australia
- Melbourne N., Victoria, Australia
Key Eligibility Criteria
- Males aged 18 years or older at time of informed consent.
- Have a histologically confirmed diagnosis of prostate cancer, and are scheduled to undergo radical prostatectomy within 28 days of screening.
- Grade Group 2-5.
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2 at Screening.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →